Methylation of 14‑3‑3σ gene and prognostic significance of 14‑3‑3σ expression in non‑small cell lung cancer

Raungrut,Pritsana; Petjaroen,Pingpond; Geater,Sarayut Lucien; Keeratichananont,Warangkana; Phukaoloun,Monlika; Suwiwat,Supaporn; Thongsuksai,Paramee

doi:10.3892/ol.2017.6881

Methylation of 14‑3‑3σ gene and prognostic significance of 14‑3‑3σ expression in non‑small cell lung cancer

Authors:
- Pritsana Raungrut
- Pingpond Petjaroen
- Sarayut Lucien Geater
- Warangkana Keeratichananont
- Monlika Phukaoloun
- Supaporn Suwiwat
- Paramee Thongsuksai
View Affiliations

Affiliations: Department of Biomedical Sciences and The Excellent Research Laboratory of Cancer Molecular Biology, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
Published online on: September 4, 2017 https://doi.org/10.3892/ol.2017.6881
Pages: 5257-5264
Copyright: © Raungrut et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of 14‑3‑3σ expression through DNA methylation has been associated with carcinogenesis and the prognosis for various cancer types. Detection of methylation of the gene in serum may be useful for diagnostic utility. The present study aimed to investigate the correlation between 14‑3‑3σ methylation level in 36 paired tumor tissues of non‑small cell lung cancer (NSCLC) and matched serum using methylation‑specific polymerase chain reaction. The prognostic significance of 14‑3‑3σ expression in 167 NSCLC was also evaluated using immunohistochemistry. Methylation of the 14‑3‑3σ gene was identified in all samples. The methylation level in the serum (mean 87.7%, range 64.6‑100%) was higher compared with tumor (mean 46.7%, range 25.3‑56.3%). However, no significant correlation between methylation levels in tissues and serums was observed (Spearman's correlation, ‑0.036; P=0.837). In the 167 tumor tissues, the majority of the cases (83.8%) exhibited negative expression. Adenocarcinoma is more likely to exhibit negative expression (91.4%) compared with squamous cell carcinoma (70.2%). No significant difference was identified in the overall survival according to 14‑3‑3σ expression status and 14‑3‑3σ expression did not demonstrated independent prognostic significance. In conclusion, NSCLC harbors certain levels of 14‑3‑3σ methylation in the tumor and the sera of patients. The clinical value of serum 14‑3‑3σ methylation should be further elucidated. Immunohistochemical expression 14‑3‑3σ protein has limited value on prognostic significance.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Attasara P and Sriplung H: Cancer incidence in Thailand. In: Cancer in Thailand Volume VI, 2004–2006Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y and Sangrajrang S: National Cancer Institute (Thailand); Bangkok: pp. 3–68. 2012
3	National Cancer Institute: SEER Cancer Statistics Review. 1975–2012 http://seer.cancer.gov/csr/1975_2012/Accessed. April;2015.
4	Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol. 16:162–172. 2006. View Article : Google Scholar : PubMed/NCBI
5	Galan JA, Geraghty KM, Lavoie G, Kanshin E, Tcherkezian J, Calabrese V, Jeschke GR, Turk BE, Ballif BA, Blenis J, et al: Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. Proc Natl Acad Sci USA. 111:E2918–E2927. 2014. View Article : Google Scholar : PubMed/NCBI
6	Dar A, Wu D, Lee N, Shibata E and Dutta A: 14-3-3 proteins play a role in the cell cycle by shielding cdt2 from ubiquitin-mediated degradation. Mol Cell Biol. 34:4049–4061. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1:3–11. 1997. View Article : Google Scholar : PubMed/NCBI
8	Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 97:6049–6054. 2000. View Article : Google Scholar : PubMed/NCBI
9	Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res. 60:4353–4357. 2000.PubMed/NCBI
10	Lodygin D and Hermeking H: The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res. 15:237–346. 2005. View Article : Google Scholar : PubMed/NCBI
11	Mhawech P, Greloz V, Assaly M and Herrmann F: Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int. 55:77–82. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
13	Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R and Amberger A: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res. 11:3274–3279. 2005. View Article : Google Scholar : PubMed/NCBI
14	Laimer K, Blassnig N, Spizzo G, Kloss F, Rasse M, Obrist P, Schäfer G, Perathoner A, Margreiter R and Amberger A: Prognostic significance of 14-3-3sigma expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 45:127–134. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK and Liu Q: Aberrant upregulation of 14-3-3o expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer. 11:3972011. View Article : Google Scholar : PubMed/NCBI
16	Qi W, Liu X, Qiao D and Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer. 113:359–63. 2005. View Article : Google Scholar : PubMed/NCBI
17	Shiba-Ishii A, Kano J, Morishita Y, Sato Y, Minami Y and Noguchi M: High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. Int J Cancer. 129:2445–2453. 2011. View Article : Google Scholar : PubMed/NCBI
18	Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi T: Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene. 21:2418–2424. 2002. View Article : Google Scholar : PubMed/NCBI
19	International Union Against Cancer (UICC): TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK and Wittekind CH: 7th. Wiley-Blackwell; Hoboken, NJ: 2009
20	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: World Health Organization Classification of TumoursPathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 3rd. IARC Press; Lyon: pp. 145–975. 2004
21	Green MR and Sambrook J: Molecular cloningA laboratory manual. 4th. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 2012
22	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
23	Luo J, Feng J, Lu J, Wang Y, Tang X, Xie F and Li W: Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis. Med Oncol. 27:791–797. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, et al: Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem. 106:858–866. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shiba-Ishii A and Noguchi M: Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma. Am J Pathol. 180:1653–1662. 2012. View Article : Google Scholar : PubMed/NCBI
26	Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, Dunning A, Garte S, Matullo G, Overvad K, et al: Amount of DNA in plasma and cancer risk: A prospective study. Int J Cancer. 111:746–749. 2004. View Article : Google Scholar : PubMed/NCBI
27	Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:67–70. 1999.PubMed/NCBI
28	Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, et al: 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol. 23:9105–9112. 2005. View Article : Google Scholar : PubMed/NCBI
29	Jylhävä J, Jylhä M, Lehtimäki T, Hervonen A and Hurme M: Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: The Vitality 90+ Study. Exp Gerontol. 47:372–378. 2012. View Article : Google Scholar : PubMed/NCBI
30	Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ and Hoon DS: Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats. Clin Chem. 52:1062–1069. 2006. View Article : Google Scholar : PubMed/NCBI
31	Liu Y, Chen Q and Zhang JT: Tumor suppressor gene 14-3-3sigma is down-regulated whereas the proto-oncogene translation elongation factor 1delta is up-regulated in non-small cell lung cancers as identified by proteomic profiling. J Proteome Res. 3:728–735. 2004. View Article : Google Scholar : PubMed/NCBI
32	Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, et al: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 10:3064–3068. 2004. View Article : Google Scholar : PubMed/NCBI
33	Ren HZ, Pan GQ, Wang JS, Wen JF, Wang KS, Luo GQ and Shan XZ: Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Dig Dis Sci. 55:2552–2560. 2010. View Article : Google Scholar : PubMed/NCBI
34	Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin Cancer Res. 10:2687–3793. 2004. View Article : Google Scholar : PubMed/NCBI
35	Li YL, Liu L, Xiao Y, Zeng T and Zeng C: 14-3-3σ is an independent prognostic biomarker for gastric cancer and is associated with apoptosis and proliferation in gastric cancer. Oncol Lett. 9:290–294. 2015.PubMed/NCBI